Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 4

Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers

Authors Paul C Edwards, John E Fantasia

Published 15 January 2008 Volume 2007:2(4) Pages 509—519


Paul C Edwards1, John E Fantasia2

1Associate Professor (Clinical), Department of Periodontics and Oral Medicine, Pathology and Oncology, University of Michigan School of Dentistry, Ann Arbor MI, USA; 2Chief, Division of Oral Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, NY, USA

Abstract: Although only recently introduced, chemically-modified hyaluronic acid dermal fillers have gained widespread acceptance as “redefining” dermal fillers in the fields of dermatology and cosmetic facial surgery. Although hyaluronic acid-based dermal fillers have a low overall incidence of long term side effects, occasional adverse outcomes, ranging from chronic lymphoplasmacytic inflammatory reactions to classic foreign body-type granulomatous reactions have been documented. These long-term adverse events are reviewed.

Keywords: hyaluronic acid, Restylane®, Hylaform®, injectable dermal filler, foreign body reaction, granuloma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Anemia associated with chronic heart failure: current concepts

Shah R, Agarwal AK

Clinical Interventions in Aging 2013, 8:111-122

Published Date: 4 February 2013

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Yee AJ, Raje NS

Clinical Interventions in Aging 2012, 7:331-338

Published Date: 3 September 2012

Descemet's stripping automated endothelial keratoplasty for congenital hereditary endothelial dystrophy

Anwar HM, El Danasoury AM, Hashem AN

Clinical Ophthalmology 2012, 6:159-163

Published Date: 24 January 2012

Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer

Jeong YI, Kim DH, Chung CW, Yoo JJ, Choi KH, Kim CH, Ha SH, Kang DH

International Journal of Nanomedicine 2011, 6:1415-1427

Published Date: 6 July 2011

Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention

Jesús Millán, Xavier Pintó, Anna Muñoz, et al

Vascular Health and Risk Management 2009, 5:757-765

Published Date: 10 September 2009


Dove Medical Press Editorial

Vascular Health and Risk Management 2009, 5:273-274

Published Date: 18 March 2009

Cardiovascular co-morbidity in rheumatic diseases

Carl Turesson, Lennart TH Jacobsson, Eric L Matteson

Vascular Health and Risk Management 2008, 4:605-614

Published Date: 6 June 2008

Antiplatelet drugs in cardiological practice: Established strategies and new developments

Florian Krötz, Hae-Young Sohn, Volker Klauss

Vascular Health and Risk Management 2008, 4:637-645

Published Date: 6 June 2008

Risk assessment for cancer surgery in elderly patients

Hodigere SJ Ramesh, Tom Boase, Riccardo A Audisio

Clinical Interventions in Aging 2006, 1:221-227

Published Date: 15 September 2006